Interaction of short peptides with FITC-labeled wheat histones and their complexes with deoxyribooligonucleotides.

Fedoreyeva LI, Smirnova TA, Kolomijtseva GY, Khavinson VKh, Vanyushin BF

Biochemistry. Biokhimiia1 Feb 2013Cited by 8 (Europe PMC)

PMID23581987DOI10.1134/s0006297913020053PepBankPUB-23581987

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study32

1 result from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cell-free)Activity measurement
In a cell-free assay, Ala-Glu-Asp-Gly (AEDG) and five other short peptides bound FITC-labeled wheat histones H1, H2B, H3 and H4, judged by fluorescence quenching.
In plain wordsIn lab tests without cells, the peptide AEDG and others bound to plant histone proteins.
Peptide
Epitalon
Outcome
Not applicableBinding to wheat histones H1, H2B, H3 and H4
Study
n: not reported in source
FITC-labeled wheat histones
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
Judging from fluorescence modulation (quenching), short peptides (Ala-Glu-Asp-Gly, Glu-Asp-Arg, Ala-Glu-Asp-Leu, Lys-Glu-Asp-Gly, Ala-Glu-Asp-Arg, and Lys-Glu-Asp-Trp) bind with FITC-labeled wheat histones H1, H2B, H3, and H4.
Report a problemFND-2358198701

Studies that did not test the peptide alone31

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

02LabNot a test of Epitalon aloneIn vitro (cell-free)Activity measurement
In a cell-free assay, peptide binding to histones and histone-oligonucleotide complexes depended on the histone and on the peptide and oligonucleotide structures, so it is site specific.
In plain wordsIn lab tests without cells, how short peptides bound histones depended on the peptide and histone structure.
Peptide
Epitalon
Outcome
Not applicableSite specificity of peptide-histone binding
Study
n: not reported in source
FITC-labeled wheat histones
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
Peptide binding with histones and histone-deoxyribooligonucleotide complexes depends on the nature of the histone and the primary structures of the peptides and oligonucleotides; thus, it is site specific.
In this study, Epitalon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Epitalon.
Report a problemFND-2358198702
03LabNot a test of Epitalon aloneIn vitro (cell-free)Activity measurement
In a cell-free assay, DNA or deoxyribooligonucleotides in a complex with histones could enhance or inhibit peptide binding.
In plain wordsIn lab tests without cells, DNA bound to histones could make peptide binding stronger or weaker.
Peptide
Epitalon
Outcome
MixedEffect of DNA on peptide-histone binding
Study
n: not reported in source
FITC-labeled wheat histones
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
DNA or deoxyribooligonucleotides in a complex with histones can enhance or inhibit peptide binding.
In this study, Epitalon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Epitalon.
Report a problemFND-2358198703
04LabNot a test of Cardiogen (AEDR) aloneIn vitro (cell-free)Mechanism
In cell-free tests, the short peptides, including Ala-Glu-Asp-Arg, bound FITC-labeled wheat histones H1, H2B, H3, and H4.
In plain wordsIn lab tests, short peptides, including Ala-Glu-Asp-Arg, bound labeled wheat histones.
Peptide
Cardiogen (AEDR)
Outcome
Not applicableBinding to wheat histones
Study
wheatn: not reported in source
FITC-labeled wheat histones and histone-deoxyribooligonucleotide complexes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
Judging from fluorescence modulation (quenching), short peptides (Ala-Glu-Asp-Gly, Glu-Asp-Arg, Ala-Glu-Asp-Leu, Lys-Glu-Asp-Gly, Ala-Glu-Asp-Arg, and Lys-Glu-Asp-Trp) bind with FITC-labeled wheat histones H1, H2B, H3, and H4.
In this study, Cardiogen (AEDR) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cardiogen (AEDR).
Report a problemFND-2358198704
05LabNot a test of Cardiogen (AEDR) aloneIn vitro (cell-free)Mechanism
In cell-free tests, short peptides, including Ala-Glu-Asp-Arg, interacted with N-terminal histone regions containing seemingly homologous peptide-binding motifs.
In plain wordsIn lab tests, short peptides, including Ala-Glu-Asp-Arg, interacted with histone end regions that contained apparently similar binding sites.
Peptide
Cardiogen (AEDR)
Outcome
Not applicableInteraction with N-terminal histone regions
Study
wheatn: not reported in source
FITC-labeled wheat histones and histone-deoxyribooligonucleotide complexes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
This results from the interaction of the peptides with the N-terminal histone regions that contain respective and seemingly homologous peptide-binding motifs.
1 context sentence(design, population, supporting numbers)
Summary · context
Judging from fluorescence modulation (quenching), short peptides (Ala-Glu-Asp-Gly, Glu-Asp-Arg, Ala-Glu-Asp-Leu, Lys-Glu-Asp-Gly, Ala-Glu-Asp-Arg, and Lys-Glu-Asp-Trp) bind with FITC-labeled wheat histones H1, H2B, H3, and H4.
In this study, Cardiogen (AEDR) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cardiogen (AEDR).
Report a problemFND-2358198705
06LabNot a test of Cardiogen (AEDR) aloneIn vitro (cell-free)Mechanism
In cell-free tests, short peptides, including Ala-Glu-Asp-Arg, seemed to bind core histone regions with specific conformational structure.
In plain wordsIn lab tests, short peptides, including Ala-Glu-Asp-Arg, seemed to bind core histone regions with a specific shape.
Peptide
Cardiogen (AEDR)
Outcome
Not applicableBinding to conformational regions of core histones
Study
wheatn: not reported in source
FITC-labeled wheat histones and histone-deoxyribooligonucleotide complexes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
Because homologous amino acid sequences in wheat core histones were not found, the peptides seem to bind with some core histone regions having specific conformational structure.
1 context sentence(design, population, supporting numbers)
Summary · context
Judging from fluorescence modulation (quenching), short peptides (Ala-Glu-Asp-Gly, Glu-Asp-Arg, Ala-Glu-Asp-Leu, Lys-Glu-Asp-Gly, Ala-Glu-Asp-Arg, and Lys-Glu-Asp-Trp) bind with FITC-labeled wheat histones H1, H2B, H3, and H4.
In this study, Cardiogen (AEDR) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cardiogen (AEDR).
Report a problemFND-2358198706
07LabNot a test of Cardiogen (AEDR) aloneIn vitro (cell-free)Mechanism
In cell-free tests, binding of short peptides, including Ala-Glu-Asp-Arg, depended on histone identity and peptide and oligonucleotide structures.
In plain wordsIn lab tests, binding of short peptides, including Ala-Glu-Asp-Arg, depended on the histone and the structures of peptides and oligonucleotides.
Peptide
Cardiogen (AEDR)
Outcome
Not applicableSite specificity of histone binding
Study
wheatn: not reported in source
FITC-labeled wheat histones and histone-deoxyribooligonucleotide complexes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
Peptide binding with histones and histone-deoxyribooligonucleotide complexes depends on the nature of the histone and the primary structures of the peptides and oligonucleotides; thus, it is site specific.
1 context sentence(design, population, supporting numbers)
Summary · context
Judging from fluorescence modulation (quenching), short peptides (Ala-Glu-Asp-Gly, Glu-Asp-Arg, Ala-Glu-Asp-Leu, Lys-Glu-Asp-Gly, Ala-Glu-Asp-Arg, and Lys-Glu-Asp-Trp) bind with FITC-labeled wheat histones H1, H2B, H3, and H4.
In this study, Cardiogen (AEDR) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cardiogen (AEDR).
Report a problemFND-2358198707
08LabNot a test of Cardiogen (AEDR) aloneIn vitro (cell-free)Mechanism
In cell-free tests, DNA or deoxyribooligonucleotides complexed with histones could enhance or inhibit binding of short peptides, including Ala-Glu-Asp-Arg.
In plain wordsIn lab tests, nucleic acids attached to histones could increase or decrease binding of short peptides, including Ala-Glu-Asp-Arg.
Peptide
Cardiogen (AEDR)
Outcome
MixedEffect of histone-associated nucleic acids on peptide binding
Study
wheatn: not reported in source
FITC-labeled wheat histones and histone-deoxyribooligonucleotide complexes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
DNA or deoxyribooligonucleotides in a complex with histones can enhance or inhibit peptide binding.
1 context sentence(design, population, supporting numbers)
Summary · context
Judging from fluorescence modulation (quenching), short peptides (Ala-Glu-Asp-Gly, Glu-Asp-Arg, Ala-Glu-Asp-Leu, Lys-Glu-Asp-Gly, Ala-Glu-Asp-Arg, and Lys-Glu-Asp-Trp) bind with FITC-labeled wheat histones H1, H2B, H3, and H4.
In this study, Cardiogen (AEDR) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cardiogen (AEDR).
Report a problemFND-2358198708
09LabNot a test of Pinealon aloneIn vitro (cell-free)Mechanism
In cell-free tests, short peptides including Glu-Asp-Arg bound FITC-labeled wheat histone H1.
In plain wordsIn lab tests, short peptides including Glu-Asp-Arg bound labeled wheat histone H1.
Peptide
Pinealon
Outcome
Not applicableBinding to histone H1
Study
wheatn: not reported in source
FITC-labeled wheat histones and histone-deoxyribooligonucleotide complexes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
Judging from fluorescence modulation (quenching), short peptides (Ala-Glu-Asp-Gly, Glu-Asp-Arg, Ala-Glu-Asp-Leu, Lys-Glu-Asp-Gly, Ala-Glu-Asp-Arg, and Lys-Glu-Asp-Trp) bind with FITC-labeled wheat histones H1, H2B, H3, and H4.
In this study, Pinealon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pinealon.
Report a problemFND-2358198709
10LabNot a test of Pinealon aloneIn vitro (cell-free)Mechanism
In cell-free tests, short peptides including Glu-Asp-Arg bound FITC-labeled wheat histone H2B.
In plain wordsIn lab tests, short peptides including Glu-Asp-Arg bound labeled wheat histone H2B.
Peptide
Pinealon
Outcome
Not applicableBinding to histone H2B
Study
wheatn: not reported in source
FITC-labeled wheat histones and histone-deoxyribooligonucleotide complexes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
Judging from fluorescence modulation (quenching), short peptides (Ala-Glu-Asp-Gly, Glu-Asp-Arg, Ala-Glu-Asp-Leu, Lys-Glu-Asp-Gly, Ala-Glu-Asp-Arg, and Lys-Glu-Asp-Trp) bind with FITC-labeled wheat histones H1, H2B, H3, and H4.
In this study, Pinealon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pinealon.
Report a problemFND-2358198710
11LabNot a test of Pinealon aloneIn vitro (cell-free)Mechanism
In cell-free tests, short peptides including Glu-Asp-Arg bound FITC-labeled wheat histone H3.
In plain wordsIn lab tests, short peptides including Glu-Asp-Arg bound labeled wheat histone H3.
Peptide
Pinealon
Outcome
Not applicableBinding to histone H3
Study
wheatn: not reported in source
FITC-labeled wheat histones and histone-deoxyribooligonucleotide complexes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
Judging from fluorescence modulation (quenching), short peptides (Ala-Glu-Asp-Gly, Glu-Asp-Arg, Ala-Glu-Asp-Leu, Lys-Glu-Asp-Gly, Ala-Glu-Asp-Arg, and Lys-Glu-Asp-Trp) bind with FITC-labeled wheat histones H1, H2B, H3, and H4.
In this study, Pinealon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pinealon.
Report a problemFND-2358198711
12LabNot a test of Pinealon aloneIn vitro (cell-free)Mechanism
In cell-free tests, short peptides including Glu-Asp-Arg bound FITC-labeled wheat histone H4.
In plain wordsIn lab tests, short peptides including Glu-Asp-Arg bound labeled wheat histone H4.
Peptide
Pinealon
Outcome
Not applicableBinding to histone H4
Study
wheatn: not reported in source
FITC-labeled wheat histones and histone-deoxyribooligonucleotide complexes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
Judging from fluorescence modulation (quenching), short peptides (Ala-Glu-Asp-Gly, Glu-Asp-Arg, Ala-Glu-Asp-Leu, Lys-Glu-Asp-Gly, Ala-Glu-Asp-Arg, and Lys-Glu-Asp-Trp) bind with FITC-labeled wheat histones H1, H2B, H3, and H4.
In this study, Pinealon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pinealon.
Report a problemFND-2358198712
13LabNot a test of Pinealon aloneIn vitro (cell-free)Mechanism
In cell-free tests, the short peptides interacted with N-terminal histone regions containing putative homologous peptide-binding motifs.
In plain wordsIn lab tests, the short peptides interacted with histone ends containing apparently similar peptide-binding sites.
Peptide
Pinealon
Outcome
Not applicableN-terminal histone interaction
Study
wheatn: not reported in source
FITC-labeled wheat histones and histone-deoxyribooligonucleotide complexes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
This results from the interaction of the peptides with the N-terminal histone regions that contain respective and seemingly homologous peptide-binding motifs.
1 context sentence(design, population, supporting numbers)
Summary · context
Judging from fluorescence modulation (quenching), short peptides (Ala-Glu-Asp-Gly, Glu-Asp-Arg, Ala-Glu-Asp-Leu, Lys-Glu-Asp-Gly, Ala-Glu-Asp-Arg, and Lys-Glu-Asp-Trp) bind with FITC-labeled wheat histones H1, H2B, H3, and H4.
In this study, Pinealon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pinealon.
Report a problemFND-2358198713
14LabNot a test of Pinealon aloneIn vitro (cell-free)Mechanism
In cell-free tests, the peptides appeared to bind core histone regions with specific conformations rather than homologous amino acid sequences.
In plain wordsIn lab tests, the peptides appeared to bind core histone regions with specific shapes.
Peptide
Pinealon
Outcome
Not applicableConformation-dependent core histone binding
Study
wheatn: not reported in source
FITC-labeled wheat histones and histone-deoxyribooligonucleotide complexes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
Because homologous amino acid sequences in wheat core histones were not found, the peptides seem to bind with some core histone regions having specific conformational structure.
1 context sentence(design, population, supporting numbers)
Summary · context
Judging from fluorescence modulation (quenching), short peptides (Ala-Glu-Asp-Gly, Glu-Asp-Arg, Ala-Glu-Asp-Leu, Lys-Glu-Asp-Gly, Ala-Glu-Asp-Arg, and Lys-Glu-Asp-Trp) bind with FITC-labeled wheat histones H1, H2B, H3, and H4.
In this study, Pinealon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pinealon.
Report a problemFND-2358198714
15LabNot a test of Pinealon aloneIn vitro (cell-free)Mechanism
In cell-free tests, peptide binding depended on histone identity and peptide and oligonucleotide primary structures.
In plain wordsIn lab tests, peptide binding depended on the histone and the sequences of peptides and oligonucleotides.
Peptide
Pinealon
Outcome
Not applicableSite-specific histone binding
Study
wheatn: not reported in source
FITC-labeled wheat histones and histone-deoxyribooligonucleotide complexes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
Peptide binding with histones and histone-deoxyribooligonucleotide complexes depends on the nature of the histone and the primary structures of the peptides and oligonucleotides; thus, it is site specific.
1 context sentence(design, population, supporting numbers)
Summary · context
Judging from fluorescence modulation (quenching), short peptides (Ala-Glu-Asp-Gly, Glu-Asp-Arg, Ala-Glu-Asp-Leu, Lys-Glu-Asp-Gly, Ala-Glu-Asp-Arg, and Lys-Glu-Asp-Trp) bind with FITC-labeled wheat histones H1, H2B, H3, and H4.
In this study, Pinealon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pinealon.
Report a problemFND-2358198715
16LabNot a test of Pinealon aloneIn vitro (cell-free)Mechanism
In cell-free histone complexes, DNA or deoxyribooligonucleotides could enhance or inhibit binding of the short peptides.
In plain wordsIn lab tests, DNA or short DNA sequences in histone complexes could increase or decrease peptide binding.
Peptide
Pinealon
Outcome
MixedDNA modulation of peptide binding
Study
wheatn: not reported in source
FITC-labeled wheat histones and histone-deoxyribooligonucleotide complexes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
DNA or deoxyribooligonucleotides in a complex with histones can enhance or inhibit peptide binding.
1 context sentence(design, population, supporting numbers)
Summary · context
Judging from fluorescence modulation (quenching), short peptides (Ala-Glu-Asp-Gly, Glu-Asp-Arg, Ala-Glu-Asp-Leu, Lys-Glu-Asp-Gly, Ala-Glu-Asp-Arg, and Lys-Glu-Asp-Trp) bind with FITC-labeled wheat histones H1, H2B, H3, and H4.
In this study, Pinealon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pinealon.
Report a problemFND-2358198716
17LabNot a test of Bronchogen (AEDL) aloneIn vitro (cell-free)Mechanism
In cell-free tests, the peptide group including Ala-Glu-Asp-Leu bound wheat histone H1.
In plain wordsIn lab tests, the peptide group including bronchogen bound wheat histone H1.
Peptide
Bronchogen (AEDL)
Outcome
Not applicableHistone H1 binding
Study
Triticumn: not reported in source
FITC-labeled wheat histones and histone–deoxyribooligonucleotide complexes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
Judging from fluorescence modulation (quenching), short peptides (Ala-Glu-Asp-Gly, Glu-Asp-Arg, Ala-Glu-Asp-Leu, Lys-Glu-Asp-Gly, Ala-Glu-Asp-Arg, and Lys-Glu-Asp-Trp) bind with FITC-labeled wheat histones H1, H2B, H3, and H4.
In this study, Bronchogen (AEDL) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Bronchogen (AEDL).
Report a problemFND-2358198717
18LabNot a test of Bronchogen (AEDL) aloneIn vitro (cell-free)Mechanism
In cell-free tests, the peptide group including Ala-Glu-Asp-Leu bound wheat histone H2B.
In plain wordsIn lab tests, the peptide group including bronchogen bound wheat histone H2B.
Peptide
Bronchogen (AEDL)
Outcome
Not applicableHistone H2B binding
Study
Triticumn: not reported in source
FITC-labeled wheat histones and histone–deoxyribooligonucleotide complexes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
Judging from fluorescence modulation (quenching), short peptides (Ala-Glu-Asp-Gly, Glu-Asp-Arg, Ala-Glu-Asp-Leu, Lys-Glu-Asp-Gly, Ala-Glu-Asp-Arg, and Lys-Glu-Asp-Trp) bind with FITC-labeled wheat histones H1, H2B, H3, and H4.
In this study, Bronchogen (AEDL) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Bronchogen (AEDL).
Report a problemFND-2358198718
19LabNot a test of Bronchogen (AEDL) aloneIn vitro (cell-free)Mechanism
In cell-free tests, the peptide group including Ala-Glu-Asp-Leu bound wheat histone H3.
In plain wordsIn lab tests, the peptide group including bronchogen bound wheat histone H3.
Peptide
Bronchogen (AEDL)
Outcome
Not applicableHistone H3 binding
Study
Triticumn: not reported in source
FITC-labeled wheat histones and histone–deoxyribooligonucleotide complexes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
Judging from fluorescence modulation (quenching), short peptides (Ala-Glu-Asp-Gly, Glu-Asp-Arg, Ala-Glu-Asp-Leu, Lys-Glu-Asp-Gly, Ala-Glu-Asp-Arg, and Lys-Glu-Asp-Trp) bind with FITC-labeled wheat histones H1, H2B, H3, and H4.
In this study, Bronchogen (AEDL) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Bronchogen (AEDL).
Report a problemFND-2358198719
20LabNot a test of Bronchogen (AEDL) aloneIn vitro (cell-free)Mechanism
In cell-free tests, the peptide group including Ala-Glu-Asp-Leu bound wheat histone H4.
In plain wordsIn lab tests, the peptide group including bronchogen bound wheat histone H4.
Peptide
Bronchogen (AEDL)
Outcome
Not applicableHistone H4 binding
Study
Triticumn: not reported in source
FITC-labeled wheat histones and histone–deoxyribooligonucleotide complexes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
Judging from fluorescence modulation (quenching), short peptides (Ala-Glu-Asp-Gly, Glu-Asp-Arg, Ala-Glu-Asp-Leu, Lys-Glu-Asp-Gly, Ala-Glu-Asp-Arg, and Lys-Glu-Asp-Trp) bind with FITC-labeled wheat histones H1, H2B, H3, and H4.
In this study, Bronchogen (AEDL) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Bronchogen (AEDL).
Report a problemFND-2358198720
21LabNot a test of Bronchogen (AEDL) aloneIn vitro (cell-free)Mechanism
In cell-free tests, binding by the peptide group including Ala-Glu-Asp-Leu involved N-terminal histone regions with putative homologous binding motifs.
In plain wordsIn lab tests, the peptide group including bronchogen interacted with the beginning regions of histones.
Peptide
Bronchogen (AEDL)
Outcome
Not applicableN-terminal histone interaction
Study
Triticumn: not reported in source
FITC-labeled wheat histones and histone–deoxyribooligonucleotide complexes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
This results from the interaction of the peptides with the N-terminal histone regions that contain respective and seemingly homologous peptide-binding motifs.
1 context sentence(design, population, supporting numbers)
Summary · context
Judging from fluorescence modulation (quenching), short peptides (Ala-Glu-Asp-Gly, Glu-Asp-Arg, Ala-Glu-Asp-Leu, Lys-Glu-Asp-Gly, Ala-Glu-Asp-Arg, and Lys-Glu-Asp-Trp) bind with FITC-labeled wheat histones H1, H2B, H3, and H4.
In this study, Bronchogen (AEDL) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Bronchogen (AEDL).
Report a problemFND-2358198721
22LabNot a test of Bronchogen (AEDL) aloneIn vitro (cell-free)Mechanism
In cell-free tests, the peptide group including Ala-Glu-Asp-Leu appeared to bind core histone regions with specific conformations.
In plain wordsIn lab tests, the peptide group including bronchogen seemed to bind regions of core histones with specific shapes.
Peptide
Bronchogen (AEDL)
Outcome
Not applicableCore histone conformational recognition
Study
Triticumn: not reported in source
FITC-labeled wheat histones and histone–deoxyribooligonucleotide complexes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
Because homologous amino acid sequences in wheat core histones were not found, the peptides seem to bind with some core histone regions having specific conformational structure.
1 context sentence(design, population, supporting numbers)
Summary · context
Judging from fluorescence modulation (quenching), short peptides (Ala-Glu-Asp-Gly, Glu-Asp-Arg, Ala-Glu-Asp-Leu, Lys-Glu-Asp-Gly, Ala-Glu-Asp-Arg, and Lys-Glu-Asp-Trp) bind with FITC-labeled wheat histones H1, H2B, H3, and H4.
In this study, Bronchogen (AEDL) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Bronchogen (AEDL).
Report a problemFND-2358198722
23LabNot a test of Bronchogen (AEDL) aloneIn vitro (cell-free)Mechanism
In cell-free tests, peptide-group binding depended on histone identity and peptide and oligonucleotide primary structures.
In plain wordsIn lab tests, binding by the peptide group including bronchogen depended on the histone, peptide structure and DNA structure.
Peptide
Bronchogen (AEDL)
Outcome
Not applicableSite-specific histone-complex binding
Study
Triticumn: not reported in source
FITC-labeled wheat histones and histone–deoxyribooligonucleotide complexes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
Peptide binding with histones and histone-deoxyribooligonucleotide complexes depends on the nature of the histone and the primary structures of the peptides and oligonucleotides; thus, it is site specific.
1 context sentence(design, population, supporting numbers)
Summary · context
Judging from fluorescence modulation (quenching), short peptides (Ala-Glu-Asp-Gly, Glu-Asp-Arg, Ala-Glu-Asp-Leu, Lys-Glu-Asp-Gly, Ala-Glu-Asp-Arg, and Lys-Glu-Asp-Trp) bind with FITC-labeled wheat histones H1, H2B, H3, and H4.
In this study, Bronchogen (AEDL) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Bronchogen (AEDL).
Report a problemFND-2358198723
24LabNot a test of Bronchogen (AEDL) aloneIn vitro (cell-free)Mechanism
In cell-free tests, DNA or deoxyribooligonucleotides in histone complexes could enhance or inhibit binding by the peptide group including Ala-Glu-Asp-Leu.
In plain wordsIn lab tests, DNA in histone complexes could increase or decrease binding by the peptide group including bronchogen.
Peptide
Bronchogen (AEDL)
Outcome
MixedDNA modulation of peptide binding
Study
Triticumn: not reported in source
FITC-labeled wheat histones and histone–deoxyribooligonucleotide complexes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
DNA or deoxyribooligonucleotides in a complex with histones can enhance or inhibit peptide binding.
1 context sentence(design, population, supporting numbers)
Summary · context
Judging from fluorescence modulation (quenching), short peptides (Ala-Glu-Asp-Gly, Glu-Asp-Arg, Ala-Glu-Asp-Leu, Lys-Glu-Asp-Gly, Ala-Glu-Asp-Arg, and Lys-Glu-Asp-Trp) bind with FITC-labeled wheat histones H1, H2B, H3, and H4.
In this study, Bronchogen (AEDL) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Bronchogen (AEDL).
Report a problemFND-2358198724
25LabNot a test of Pancragen (KEDW) aloneIn vitro (cell-free)Mechanism
In cell-free tests, the peptide panel including Lys-Glu-Asp-Trp bound FITC-labeled wheat histone H1, as assessed by fluorescence quenching.
In plain wordsIn lab tests, the peptide panel including Lys-Glu-Asp-Trp bound wheat histone H1.
Peptide
Pancragen (KEDW)
Outcome
Not applicableHistone H1 binding
Study
wheatn: not reported in source
FITC-labeled wheat histones and histone-deoxyribooligonucleotide complexes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
Judging from fluorescence modulation (quenching), short peptides (Ala-Glu-Asp-Gly, Glu-Asp-Arg, Ala-Glu-Asp-Leu, Lys-Glu-Asp-Gly, Ala-Glu-Asp-Arg, and Lys-Glu-Asp-Trp) bind with FITC-labeled wheat histones H1, H2B, H3, and H4.
In this study, Pancragen (KEDW) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pancragen (KEDW).
Report a problemFND-2358198725
26LabNot a test of Pancragen (KEDW) aloneIn vitro (cell-free)Mechanism
In cell-free tests, the peptide panel including Lys-Glu-Asp-Trp bound FITC-labeled wheat histone H2B, as assessed by fluorescence quenching.
In plain wordsIn lab tests, the peptide panel including Lys-Glu-Asp-Trp bound wheat histone H2B.
Peptide
Pancragen (KEDW)
Outcome
Not applicableHistone H2B binding
Study
wheatn: not reported in source
FITC-labeled wheat histones and histone-deoxyribooligonucleotide complexes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
Judging from fluorescence modulation (quenching), short peptides (Ala-Glu-Asp-Gly, Glu-Asp-Arg, Ala-Glu-Asp-Leu, Lys-Glu-Asp-Gly, Ala-Glu-Asp-Arg, and Lys-Glu-Asp-Trp) bind with FITC-labeled wheat histones H1, H2B, H3, and H4.
In this study, Pancragen (KEDW) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pancragen (KEDW).
Report a problemFND-2358198726
27LabNot a test of Pancragen (KEDW) aloneIn vitro (cell-free)Mechanism
In cell-free tests, the peptide panel including Lys-Glu-Asp-Trp bound FITC-labeled wheat histone H3, as assessed by fluorescence quenching.
In plain wordsIn lab tests, the peptide panel including Lys-Glu-Asp-Trp bound wheat histone H3.
Peptide
Pancragen (KEDW)
Outcome
Not applicableHistone H3 binding
Study
wheatn: not reported in source
FITC-labeled wheat histones and histone-deoxyribooligonucleotide complexes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
Judging from fluorescence modulation (quenching), short peptides (Ala-Glu-Asp-Gly, Glu-Asp-Arg, Ala-Glu-Asp-Leu, Lys-Glu-Asp-Gly, Ala-Glu-Asp-Arg, and Lys-Glu-Asp-Trp) bind with FITC-labeled wheat histones H1, H2B, H3, and H4.
In this study, Pancragen (KEDW) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pancragen (KEDW).
Report a problemFND-2358198727
28LabNot a test of Pancragen (KEDW) aloneIn vitro (cell-free)Mechanism
In cell-free tests, the peptide panel including Lys-Glu-Asp-Trp bound FITC-labeled wheat histone H4, as assessed by fluorescence quenching.
In plain wordsIn lab tests, the peptide panel including Lys-Glu-Asp-Trp bound wheat histone H4.
Peptide
Pancragen (KEDW)
Outcome
Not applicableHistone H4 binding
Study
wheatn: not reported in source
FITC-labeled wheat histones and histone-deoxyribooligonucleotide complexes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
Judging from fluorescence modulation (quenching), short peptides (Ala-Glu-Asp-Gly, Glu-Asp-Arg, Ala-Glu-Asp-Leu, Lys-Glu-Asp-Gly, Ala-Glu-Asp-Arg, and Lys-Glu-Asp-Trp) bind with FITC-labeled wheat histones H1, H2B, H3, and H4.
In this study, Pancragen (KEDW) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pancragen (KEDW).
Report a problemFND-2358198728
29LabNot a test of Pancragen (KEDW) aloneIn vitro (cell-free)Mechanism
In cell-free tests, the peptide panel including Lys-Glu-Asp-Trp interacted with N-terminal histone regions containing respective, seemingly homologous peptide-binding motifs.
In plain wordsIn lab tests, the peptide panel including Lys-Glu-Asp-Trp interacted with histone end regions containing seemingly similar binding motifs.
Peptide
Pancragen (KEDW)
Outcome
Not applicableN-terminal histone interaction
Study
wheatn: not reported in source
FITC-labeled wheat histones and histone-deoxyribooligonucleotide complexes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
This results from the interaction of the peptides with the N-terminal histone regions that contain respective and seemingly homologous peptide-binding motifs.
1 context sentence(design, population, supporting numbers)
Summary · context
Judging from fluorescence modulation (quenching), short peptides (Ala-Glu-Asp-Gly, Glu-Asp-Arg, Ala-Glu-Asp-Leu, Lys-Glu-Asp-Gly, Ala-Glu-Asp-Arg, and Lys-Glu-Asp-Trp) bind with FITC-labeled wheat histones H1, H2B, H3, and H4.
In this study, Pancragen (KEDW) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pancragen (KEDW).
Report a problemFND-2358198729
30LabNot a test of Pancragen (KEDW) aloneIn vitro (cell-free)Mechanism
In cell-free tests, the peptide panel including Lys-Glu-Asp-Trp seemed to bind core histone regions with specific conformations despite absent homologous sequences.
In plain wordsIn lab tests, the peptide panel including Lys-Glu-Asp-Trp seemed to bind specifically shaped core histone regions despite absent matching sequences.
Peptide
Pancragen (KEDW)
Outcome
Not applicableCore histone binding regions
Study
wheatn: not reported in source
FITC-labeled wheat histones and histone-deoxyribooligonucleotide complexes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
Because homologous amino acid sequences in wheat core histones were not found, the peptides seem to bind with some core histone regions having specific conformational structure.
1 context sentence(design, population, supporting numbers)
Summary · context
Judging from fluorescence modulation (quenching), short peptides (Ala-Glu-Asp-Gly, Glu-Asp-Arg, Ala-Glu-Asp-Leu, Lys-Glu-Asp-Gly, Ala-Glu-Asp-Arg, and Lys-Glu-Asp-Trp) bind with FITC-labeled wheat histones H1, H2B, H3, and H4.
In this study, Pancragen (KEDW) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pancragen (KEDW).
Report a problemFND-2358198730
31LabNot a test of Pancragen (KEDW) aloneIn vitro (cell-free)Mechanism
In cell-free tests, panel peptide binding depended on histone identity and peptide and oligonucleotide sequences, indicating site specificity.
In plain wordsIn lab tests, panel peptide binding depended on histone type and peptide and oligonucleotide sequences.
Peptide
Pancragen (KEDW)
Outcome
Not applicableSite specificity of peptide binding
Study
wheatn: not reported in source
FITC-labeled wheat histones and histone-deoxyribooligonucleotide complexes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
Peptide binding with histones and histone-deoxyribooligonucleotide complexes depends on the nature of the histone and the primary structures of the peptides and oligonucleotides; thus, it is site specific.
1 context sentence(design, population, supporting numbers)
Summary · context
Judging from fluorescence modulation (quenching), short peptides (Ala-Glu-Asp-Gly, Glu-Asp-Arg, Ala-Glu-Asp-Leu, Lys-Glu-Asp-Gly, Ala-Glu-Asp-Arg, and Lys-Glu-Asp-Trp) bind with FITC-labeled wheat histones H1, H2B, H3, and H4.
In this study, Pancragen (KEDW) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pancragen (KEDW).
Report a problemFND-2358198731
32LabNot a test of Pancragen (KEDW) aloneIn vitro (cell-free)Mechanism
In cell-free tests, DNA or deoxyribooligonucleotides complexed with histones could enhance or inhibit binding of panel peptides including Lys-Glu-Asp-Trp.
In plain wordsIn lab tests, DNA or short DNA strands complexed with histones could increase or decrease binding of panel peptides including Lys-Glu-Asp-Trp.
Peptide
Pancragen (KEDW)
Outcome
MixedModulation of peptide binding by nucleic acids
Study
wheatn: not reported in source
FITC-labeled wheat histones and histone-deoxyribooligonucleotide complexes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
DNA or deoxyribooligonucleotides in a complex with histones can enhance or inhibit peptide binding.
1 context sentence(design, population, supporting numbers)
Summary · context
Judging from fluorescence modulation (quenching), short peptides (Ala-Glu-Asp-Gly, Glu-Asp-Arg, Ala-Glu-Asp-Leu, Lys-Glu-Asp-Gly, Ala-Glu-Asp-Arg, and Lys-Glu-Asp-Trp) bind with FITC-labeled wheat histones H1, H2B, H3, and H4.
In this study, Pancragen (KEDW) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pancragen (KEDW).
Report a problemFND-2358198732

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 11 to 18Current
28 Oct 2026, 02:02 UTC
The same notice was added 8 times, first on 21 Oct 2026, 17:05 UTC. The status did not change between them.
Study results updated
Versions 8 to 10
21 Oct 2026, 16:35 UTC
The same notice was added 3 times, first on 21 Oct 2026, 16:35 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Versions 5 to 7
21 Oct 2026, 15:58 UTC
The same notice was added 3 times, first on 14 Oct 2026, 05:02 UTC. The status did not change between them.
Study results updated
Versions 3 to 4
14 Oct 2026, 01:46 UTC
The same notice was added 2 times, first on 14 Oct 2026, 01:46 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 2
10 Oct 2026, 08:19 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC